

450 Supplementary Information for
451 **Comparison of Saliva and Mid-Turbinate Swabs for Detection of COVID-19**

452
453 Jianyu Lai, B.Med., M.P.H.^{a,b}, Jennifer German, Ph.D.^b, Filbert Hong, Ph.D.^b, S.-H. Sheldon Tai,
454 Ph.D.^b, Kathleen M. McPhaul, Ph.D., M.P.H.^b, Donald K. Milton, M.D., Dr.P.H.^b for the
455 University of Maryland StopCOVID Research Group*

456
457 ^a Department of Epidemiology and Biostatistics, University of Maryland School of Public
458 Health, College Park, Maryland, USA

459 ^b Public Health Aerobiology and Biomarker Laboratory, Institute for Applied Environmental
460 Health, University of Maryland School of Public Health, College Park, Maryland, USA

461

462 Supplemental Tables

463

464 Table S1. Association between detection frequency and sample types (MTS vs. saliva) ^a

465

<i>Sample Positive</i>	<i>Sample Type</i>		<i>Total</i>
	MTS	Saliva	
No	171	168	339
Yes	29	32	61
<i>Total</i>	200	200	400

^a $\chi^2=0.077$, $df=1$, $p=0.781$

466

467 Table S2. MTS and saliva for positive participants (N=14)
 468

	Number of subjects	Number of samples	Number of positive samples, N (%)	Ct value of positive samples, median (range) ^a	GM (95% CI) ^b of all samples	GM (95% CI) ^c of positive samples
MTS	13	41	29 (71)	20 (12, 33)	2.2 x10 ⁵ (1.0 x10 ⁵ , 4.9 x10 ⁵)	4.5 x10 ⁶ (3.5 x10 ⁶ , 5.9 x10 ⁶)
Saliva	12	41	32 (78)	27 (16, 35)	2.3 x10 ³ (1.2 x10 ³ , 4.3 x10 ³)	4.5 x10 ⁵ (4.0 x10 ⁵ , 5.0 x10 ⁵)

469 ^a. A positive sample was defined as having Ct < 40 in PCR detection for at least two out of three
 470 SARS-CoV-2 genes (N, S, ORF1ab)

471 ^b. GM = geometric mean. The GMs were computed, accounting for samples below the LOD,
 472 using a linear mixed-effects model for censored responses (R Project LMEC package) using data
 473 for all samples of each sample type with nested random effects of samples within study
 474 participant.

475 ^c. GM were calculated using data from only positive samples of each sample type with nested
 476 random effects of samples within study participant.

477 Table S3a. Viral RNA detection in paired saliva and MTS samples from participants with one or
 478 more positive samples (N=14) ^a

<i>Saliva Positive</i>	<i>MTS Positive</i>		<i>Total</i>
	No	Yes	
No	6	3	9
Yes	6	26	32
<i>Total</i>	12	29	41

479 ^a Cohen's Kappa between the two sample types was calculated as $\kappa=0.43$

480

481

482 Table S3b. Viral RNA detection in paired saliva and MTS samples from symptomatic
 483 participants with one or more positive samples (N=13) ^a

484

<i>Saliva Positive</i>	<i>MTS Positive</i>		<i>Total</i>
	No	Yes	
No	6	3	9
Yes	6	25	31
<i>Total</i>	12	28	40

485 ^a Cohen's Kappa between the two sample types was calculated as $\kappa=0.42$


486

487 Table S4. Saliva and MTS testing results for the asymptomatic positive participant (N=1)


	Ngene Ct	Orflab Ct	Sgene Ct	Average Ct
MTS	26.7	25.2	25.6	25.8
Saliva	33.4	36.3	34.5	34.7

488

489 Supplemental Figures
490



491
492 Figure S1. Distribution of Ct values by sample types among 58 participants and 400 samples.
493



494

495 Figure S2. Distribution of samples from 13 symptomatic positive cases by days since symptom
 496 onset. A) Days -3 through 2, B) Days 3 through 8, C) Days 8 through 24.